Pathways by which interleukin 17 induces articular cartilage breakdown in vitro and in vivo

Cytokine

Volumn 16, Issue 1, 2001, Pages 10-21

  Cai, Liping ^a   Yin, Jianping ^a   Starovasnik, Melissa A ^a   Hogue, Deborah A ^a   Hillan, Kenneth J ^a   Mort, John S ^b   Filvaroff, Ellen H ^a  

^a GENENTECH INC   (United States)

^b SHRINERS HOSPITAL FOR CHILDREN   (Canada)

Author keywords

Cartilage; Cytokines; Interleukins; Rheumatoid arthritis; T lymphocytes

Indexed keywords

AGGRECANASE; INTERLEUKIN 17; LEUKEMIA INHIBITORY FACTOR; MATRIX METALLOPROTEINASE;

ANIMAL CELL; ANIMAL TISSUE; ARTHRITIS; ARTICLE; ARTICULAR CARTILAGE; BIOSYNTHESIS; CARTILAGE CELL; CATABOLISM; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; KNEE; NONHUMAN; OSTEOARTHRITIS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM; SIMULATION;

EID: 0035554955     PISSN: 10434666     EISSN: None     Source Type: Journal    
DOI: 10.1006/cyto.2001.0939     Document Type: Article

References (40)

1. Cytokines and cytokine inhibitors or antagonists in rheumatoid arthritis
2. Inhibition of the production and effects of interleukin-1 and tumor necrosis factor-α in rheumatoid arthritis
3. Anti-tumor necrosis factor-alpha therapy of rheumatoid arthritis
4. IL-1αβ blockade prevents cartilage and bone destruction in murine type II collagen-induced arthritis, whereas TNF-α blockade only ameliorates joint inflammation
5. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist
6. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand
7. The importance of the T cell in initiating and maintaining the chronic synovitis of rheumatoid arthritis
8. Joint destruction in rheumatoid arthritis: Biological bases
9. Are T cells in rheumatoid synovium aggressors or bystanders?
10. Human interleukin-17: A T-cell derived proinflammatory cytokine produced by the rheumatoid synovium
11. IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis
12. High levels of IL-17 in rheumatoid arthritis patients: IL-15 triggers in vitro IL-17 production via cyclosporin A-sensitive mechanism
13. Interleukin-17 up-regulation of nitric oxide production in human osteoarthritis cartilage
14. Interleukin-17 induced gene expression in articular chondrocytes is associated with activation of mitogen-activated protein kinases and NF-κB
15. Enhancing effect of IL-17 on IL-1-induced IL-6 and leukemia inhibitory factor production by rheumatoid arthritis synoviocytes and its regulation by Th2 cytokines
16. T-cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines
17. IL-17 stimulates the production and expression of proinflammatory cytokines. IL-beta and TNF-alpha, by human macrophages
18. Mitogen-activated protein kinase and nuclear factor κB together regulate interleukin-17-induced nitric oxide production in human osteoarthritic chondrocytes
19. Contribution of interleukin 17 to synovium matrix destruction in rheumatoid arthritis
20. Cloning and characterization of IL-17B and IL-17C, two new members of the IL-17 cytokine family
21. IL-17E, a novel proinflammatory ligand for the IL-17 receptor homolog IL-17Rh1
22. Natural bovine osteogenin and recombinant human bone morphogenetic protein-2B are equipotent in the maintenance of proteoglycans in bovine articular cartilage explant cultures
23. Differential expression of aggrecanase and matrix metallopro-teinase activity in chondrocytes isolated from bovine and porcine articular cartilage
24. The mechanism of aggrecan release from cartilage differs with tissue origin and the agent used to stimulate catabolism
25. Reduction of interleukin-17-induced inhibition of chondrocyte proteoglycan synthesis in intact murine articular cartilage by interleukin 4
26. Effect of interleukin 17 on proteoglycan degradation in murine knee joints
27. IL-17 is produced by some proinflammatory Th1/Th0 cells but not by Th2 cells
28. Induction of cytokine expression by leukemia inhibitory factor
29. Leukemia inhibitory factor is expressed in cartilage and synovium and can contribute to the pathogenesis of arthritis
30. Production of leukemia inhibitory factor by human articular chondrocytes and cartilage in response to interleukin-1 and tumor necrosis factor alpha
31. Degradative enzymes in osteoarthritis
32. The structure of aggrecan fragments in human synovial fluid. Evidence for the involvement in osteoarthritis of a novel proteinase which cleaves the Glu373-Ala 374 bond of the interglobular domain
33. The structure of aggrecan fragments in human synovial fluid. Evidence that aggrecanase mediates cartilage degradation in inflammatory joint disease, joint injury, and osteoarthritis
34. Aggrecan degradation in human cartilage. Evidence for both matrix metalloproteinase and aggrecanase activity in normal, osteoarthritic, and rheumatoid joints
35. Stimulation of 92-kd gelatinase (matrix metalloproteinase 9) production by interleukin-17 in human monocyte/macrophages
36. Aggrecanase versus matrix metalloproteinases in the catabolism of the interglobular domain of aggrecan in vitro
37. Detection of human leukemia inhibitory factor by monoclonal antibody based ELISA
38. Improved quantitation and discrimination of sulphated glycosaminoglycans by use of dimethylmethylene blue
39. Assay of proteoglycan degradation
40. Kinetics of proteoglycan turnover in bovine articular cartilage explants